Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs DENTSPLY SIRONA Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.36, while DENTSPLY SIRONA Inc trades at $13.88 (market cap $2.68B). The key difference: DENTSPLY SIRONA Inc pays a 5.04% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none, and DENTSPLY SIRONA Inc is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| FEPI | XRAY | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $16.85 |
52-Week Low | $38.13 | $9.64 |
Market Cap | — | $2.68B |
Enterprise Value | — | $4.83B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI trades at $41.40, down 2.45% over the past day, with technical indicators signaling a bearish trend. The ETF generates a high yield through weekly covered call distributions, but its concentrated tech holdings and call-writing strategy cap upside potential while exposing investors to net asset value erosion during market downturns. Recent news highlights its 25% yield appeal but cautions on structural limitations.
Outlook remains cautious due to the ETF's high-risk income strategy; opportunities exist for yield-seeking investors comfortable with capped gains and volatility, but risks include underperformance versus benchmarks and NAV decay in declining markets. Investor sentiment is mixed, balancing high income against long-term growth constraints.
XRAY trades at $13.76, up 8.35% in 24 hours, with technical indicators showing a bullish trend. The stock has missed earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.36. Revenue declined to $3.68 billion in 2025, and the company reported a net loss of $598 million. Recent news highlights include distribution expansions and new AI-enabled product launches, while analyst sentiment remains mixed with a consensus price target of $13.33.
The outlook for XRAY is cautious due to persistent earnings misses and negative profitability, though technical momentum and strategic initiatives offer some upside potential. Key risks include margin pressure, high debt levels, and soft European demand. Investors should weigh the bullish technical signals against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
